EMA says no new patients should be started on Esyma for uterine fibroids

EMA says no new patients should be started on Esyma for uterine fibroids

February 13 2018 Doctors should not initiate Esyma (ulipristal acetate) in women with uterine...

New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

February 13 2018 The European Medicines Agency has issued new recommendations regarding use of...

EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

February 12 2018 The European Medicines Agency has updated advice regarding the use of retinoids...

New Drug Safety Update issued on need for contraception with mycophenolate mofetil

New Drug Safety Update issued on need for contraception with mycophenolate mofetil

February 9 2018 The medicines regulator has issued a Drug Safety Update relating to mycophenolate...

Study flags up concerns over antibiotic resistance in children's E coli in urinary infections

Study flags up concerns over antibiotic resistance in children's E coli in urinary infections

February 8 2018 Antibiotic resistance in children’s E. coli is high against many...

  • EMA says no new patients should be started on Esyma for uterine fibroids

    EMA says no new patients should be started on Esyma for uterine fibroids

    Tuesday, 13 February 2018 12:18
  • New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

    New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

    Tuesday, 13 February 2018 12:11
  • EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

    EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

    Monday, 12 February 2018 14:21
  • New Drug Safety Update issued on need for contraception with mycophenolate mofetil

    New Drug Safety Update issued on need for contraception with mycophenolate mofetil

    Friday, 09 February 2018 15:01
  • Study flags up concerns over antibiotic resistance in children's E coli in urinary infections

    Study flags up concerns over antibiotic resistance in children's E coli in urinary infections

    Thursday, 08 February 2018 10:39

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

insulinMay 11 2016

Serious health risks in type 2 diabetes may be reduced more effectively with insulin and metformin than insulin on its own, researchers have suggested.

Combination therapy resulted in a lower risk of death and major adverse cardiac events (MACE) than insulin monotherapy, the retrospective cohort study found. However, any impact on cancer was less pronounced.

The study by researchers from The Institute of Primary Care and Public Health at Cardiff University has been published on PLoS One. They analysed data from 12,020 patients, among whom 6,484 were treated with insulin monotherapy and 5,536 were prescribed insulin plus metformin. Subjects were followed for an average of 3.5 years.

Overall, there were 1,486 deaths, 579 MACE and 680 cancer events, and the corresponding event rates per 1,000 person years were 41.5 deaths, 20.8 MACE and 21.6 cancer events.

When the different cohorts were compared, the adjusted hazard ratios (aHRs) for people using combination therapy compared to insulin monotherapy were 0.60 for all cause mortality, 0.75 for MAC and 0.96 for cancer. When patients were compared in terms of event propensity, the aHRs were 0.62 for deaths, and 0.99 for cancer. For MACE, the propensity aHRs changed with time, being 1.06 before 3.5 years and 1.87 after 3.5 years.

Although the data looked specifically for patients with type 2 diabetes who had either started therapy with insulin either on its own or in combination with metformin, all patients were prescribed at least two different classes of glucose-lowering medication other than insulin. Other exclusion criteria included people who had a yearly average insulin dose greater than 4 units/kg/day, and patients with an existing history of cancer or large vessel disease, such as myocardial infarction, stroke, or angina.

Among the findings of the study were that those prescribed higher dose insulin monotherapy had the highest MACE risk, with an aHR of 1.46 compared to the lowest risk category of low-dose insulin plus metformin. The researchers noted that high-dose insulin was associated with a higher risk of cancer, but the results were not statistically significant.

Discussing the findings, the researchers say: “Among its purported benefits, metformin may be cardioprotective, an effect that cannot be solely explained by its ability to lower blood glucose. Systematic reviews have reported that insulin plus metformin cause improved glycaemic control, less weight gain, and reduced insulin requirements when compared with insulin monotherapy.”

However, the researchers acknowledge that in selecting data from patients who had been initiated on insulin and the fact that metformin may not always be indicated due to other conditions a patient may have, “the population of people receiving insulin in combination with metformin may be healthier than the monotherapy group.”

Link:

SE Holden at al. ‘Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study’. PLoS One. Published online May 6 2016

Clinical News

  February 20 2018 A covert study of pharmacies has claimed that some pharmacies are failing to give adequate safety warnings when selling analgesics and cold remedies. The Consumer Association’s...
February 19 2018 Pharmacists should be receiving educational material this week on a new patient safety campaign from the Centre of Pharmacy Postgraduate Education. Resources have been mailed out ahead...